# Perrigo to Present at the Canaccord 46th Annual Growth Conference
Canonical URL: https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922
Ticker: PRGO
Company: Perrigo Company PLC
Source: Perrigo Company PLC
Published: 2026-07-29 12:30 EST
Original Source URL: https://investor.perrigo.com/2026-07-29-Perrigo-to-Present-at-the-Canaccord-46th-Annual-Growth-Conference
## Summary

Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to present...

## Article Body
DUBLIN , July 29, 2026 / PRNewswire / -- Perrigo Company plc (NYSE: PRGO), a leading provider of consumer self-care products, today announced that Interim President and CEO Albert Manzone and CFO Eduardo Bezerra are scheduled to present at the Canaccord 46th Annual Growth Conference, on Wednesday, August 12th at 10:30 AM EDT.

The webcast can be accessed on the Perrigo website at http://perrigo.investorroom.com/events-webcasts .

About Perrigo

Perrigo Company plc is a leading pure-play self-care company with over a century of experience in providing high-quality health and wellness solutions to consumers primarily in North America and Europe. As a pioneer in the over-the-counter (OTC) self-care market, Perrigo offers trusted self-care solutions that can be used without the need for a prescription, ensuring accessibility and choice for consumers across molecules, dosage forms, and value tiers.

Perrigo's unique business model leverages its complementary businesses, where cash-generative store brand private label offerings fuel investments for leading brands, including Opill ® , Mederma ® , Compeed ® , EllaOne ® , and Jungle Formula ® .

For more information, visit www.perrigo.com .

Forward-Looking Statements

This press release includes, and the matters discussed in Perrigo's presentation at the Canaccord 46th Annual Growth Conference will include certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements involve known and unknown risks, uncertainties and other factors—many of which are beyond the Company's control—that may cause the actual results, performance or achievements of the Company to be materially different from its current expectations, assumptions, estimates and projections. Interested persons are urged to consult the Company's filings with the United States Securities and Exchange Commission, available at https://investor.perrigo.com/sec-filings , for a discussion of the Company's business and financial condition and certain material trends, risks, uncertainties and other factors relating thereto, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended December 31, 2025.

Perrigo Contacts

Eric Jacobson, Vice President, Global Investor Relations (616) 886-0375, eric.jacobson@perrigo.com

Nick Gallagher, Associate Director, Global Investor Relations (269) 686-3238, nicholas.gallagher@perrigo.com

SOURCE Perrigo Company plc
## Recent Company News
- 2026-07-29 12:30 EST — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922) — Source: Perrigo Company PLC
- 2026-07-22 12:30 EST — [Perrigo to Release Second Quarter 2026 Financial Results on August 5, 2026](https://biopharmsignal.com/news/PRGO/perrigo-to-release-second-quarter-2026-financial-results-on-august-5-2026-ff2ea2a5) — Source: Perrigo Company PLC
- 2026-06-30 20:25 EST — [Perrigo Announces Appointment of Two New Independent Directors to Board](https://biopharmsignal.com/news/PRGO/perrigo-announces-appointment-of-two-new-independent-directors-to-board-47cee7b5) — Source: Perrigo Company PLC
- 2026-06-08 20:31 EST — [Perrigo Announces Leadership Transition](https://biopharmsignal.com/news/PRGO/perrigo-announces-leadership-transition-fef2604a) — Source: Perrigo Company PLC
- 2026-05-26 12:30 EST — [Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-oppenheimer-26th-annual-consumer-growth-and-e-commerce-conference) — Source: Perrigo Company PLC
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)